These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25723557)

  • 21. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".
    Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Reddy KR; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
    J Hepatol; 2020 Mar; 72(3):592-593. PubMed ID: 31889556
    [No Abstract]   [Full Text] [Related]  

  • 22. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
    Braitstein P; Montessori V; Chan K; Montaner JS; Schechter MT; O'Shaughnessy MV; Hogg RS
    AIDS Care; 2005 May; 17(4):505-15. PubMed ID: 16036236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons.
    Mocroft A; Ryom L; Oprea C; Li Q; Rauch A; Boesecke C; Uzdaviniene V; Sedlacek D; Llibre JM; Lacombe K; Nielsen LN; Florence E; Aho I; Chkhartishvili N; Szlavik J; Dragovic G; Leen C; Sambatakou H; Staub T; Laguno M; Elinav H; Tomažič J; Peters L;
    AIDS; 2020 Aug; 34(10):1485-1495. PubMed ID: 32675562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.
    John-Baptiste AA; Tomlinson G; Hsu PC; Krajden M; Heathcote EJ; Laporte A; Yoshida EM; Anderson FH; Krahn MD
    Am J Gastroenterol; 2009 Oct; 104(10):2439-48. PubMed ID: 19568230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dualities of living with HIV/HCV co-infection: patients' perspectives from those who are ineligible for or nonresponsive to treatment.
    Farrell G; Comiskey C
    J Assoc Nurses AIDS Care; 2014; 25(1):9-22. PubMed ID: 23340239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.
    Cescon A; Chan K; Raboud JM; Burchell AN; Forrest JI; Klein MB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS; Cooper C;
    AIDS; 2014 Jan; 28(1):121-7. PubMed ID: 24413263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perceived health-related quality of life in people living with HIV co-infected with SARS-CoV-2 in France.
    Amboise Y; Yaya I; Yombo-Kokule L; Roucoux G; Ossima AN; Preau M; Griffith JW; Marcellin F; Chassany O; Cheret A; Duracinsky M
    Qual Life Res; 2024 Sep; 33(9):2529-2539. PubMed ID: 38865069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
    Vogel M; Bertram N; Wasmuth JC; Wyen C; Voigt E; Schwarze-Zander C; Sudhop T; Fätkenheuer G; Rockstroh JK; Reichel C
    J Antimicrob Chemother; 2009 May; 63(5):988-91. PubMed ID: 19270314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
    Barré T; Zucman D; Marcellin F; Ramier C; Protopopescu C; Tardieu R; Ory K; Salmon-Céron D; Carrieri P;
    J Viral Hepat; 2023 Nov; 30(11):897-900. PubMed ID: 37357886
    [No Abstract]   [Full Text] [Related]  

  • 31. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008.
    Michel L; Villes V; Dabis F; Spire B; Winnock M; Loko MA; Poizot-Martin I; Valantin MA; Bonnard P; Salmon-Céron D; Carrieri MP;
    J Viral Hepat; 2010 Sep; 17(9):650-60. PubMed ID: 20002565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human immunodeficiency virus and coinfection with hepatitis B and C.
    Petty LA; Steinbeck JL; Pursell K; Jensen DM
    Infect Dis Clin North Am; 2014 Sep; 28(3):477-99. PubMed ID: 25151567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus.
    Bhagat V; Foont JA; Schiff ER; Regev A
    Liver Transpl; 2008 Jan; 14(1):92-5. PubMed ID: 18161776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample.
    Kanwal F; Gralnek IM; Hays RD; Dulai GS; Spiegel BM; Bozzette S; Asch S
    Am J Gastroenterol; 2005 Sep; 100(9):1984-94. PubMed ID: 16128943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
    Rossotti R
    J Viral Hepat; 2023 Nov; 30(11):901. PubMed ID: 37434464
    [No Abstract]   [Full Text] [Related]  

  • 37. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP;
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A switch to Raltegravir improves antiretroviral associated hepatotoxicity in individuals co-infected with HIV and hepatitis C.
    Cevik M; Katsarolis I; Singh GJ; Nelson M
    J Infect; 2014 Aug; 69(2):190-3. PubMed ID: 24793307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
    Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
    J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
    Pockros PJ; Shiffman ML; Schiff ER; Sulkowski MS; Younossi Z; Dieterich DT; Wright TL; Mody SH; Tang KL; Goon BL; Bowers PJ; Leitz G; Afdhal NH;
    Hepatology; 2004 Dec; 40(6):1450-8. PubMed ID: 15565613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.